Eli Lilly's Retatrutide: A Breakthrough in Obesity and Osteoarthritis Treatment

Eli Lilly's experimental drug, retatrutide, has demonstrated significant efficacy in treating obesity and knee osteoarthritis, according to results from the Phase 3 TRIUMPH-4 clinical trial. Participants taking the highest dose of 12 mg lost an average of 28.7% of their body weight, equating to approximately 71.2 pounds, over a 68-week period. The trial involved 445 adults with obesity and knee osteoarthritis, with 84% of participants having a body mass index (BMI) of 35 or higher.

Lilly reports promising results from its weight-loss drug trialLilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trialMedCity NewsCNBC

The TRIUMPH-4 trial reported substantial improvements in both weight loss and pain relief. The drug reduced knee pain, as measured by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), by an average of 75.8%. Notably, over 12% of participants on the highest dose reported being completely free from knee pain by the end of the trial. The lower dose of 9 mg also yielded impressive results, with participants losing an average of 26.4% of their body weight.

Lilly reports promising results from its weight-loss drug trial

Despite the promising results, the trial revealed a higher-than-expected discontinuation rate due to side effects. Approximately 18.2% of participants on the 12 mg dose discontinued treatment, compared to 4% in the placebo group. Common side effects included gastrointestinal issues such as nausea (43.2%), diarrhea (33.1%), and dysesthesia, an abnormal skin sensation, reported by 20.9% of patients on the highest dose. Some participants cited "perceived excessive weight loss" as a reason for discontinuation, particularly among those with lower baseline BMIs.

CNBC

Kenneth Custer, president of Lilly Cardiometabolic Health, expressed optimism about the trial's results, stating, "We are encouraged by the results of TRIUMPH-4, which highlight the powerful effect of retatrutide on body weight, pain, and physical function." Analysts have noted that the results exceeded expectations, with BMO Capital Markets calling it "the highest weight loss to date" for an obesity medication.

Pharmaphorum

While the results are promising, some experts have raised concerns about the safety profile of retatrutide. Dr. David Felson, a rheumatologist at Boston University Medical Center, emphasized the need for further data on the drug's effectiveness in a broader population, particularly those with lower weights who were not represented in the trial. Additionally, some analysts have cautioned that the high discontinuation rates could complicate future studies and market acceptance.

Gizmodo

Eli Lilly plans to conduct seven additional Phase 3 trials evaluating retatrutide's efficacy in various conditions related to obesity, including type 2 diabetes and obstructive sleep apnea, with results expected by the end of 2026. The company aims to position retatrutide as a leading option for patients requiring significant weight loss and relief from complications like knee osteoarthritis.

PharmaphorumLilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trialLilly reports promising results from its weight-loss drug trialBenzinga

The TRIUMPH-4 trial results for Eli Lilly's retatrutide mark a significant advancement in obesity treatment, showcasing its potential to deliver substantial weight loss and pain relief. However, the associated side effects and discontinuation rates warrant careful consideration as the drug moves closer to potential regulatory approval. As further trials are conducted, retatrutide could reshape the landscape of obesity and osteoarthritis management.

Pharmaphorum